Glucagon-like Peptide-1 (GLP-1) Agonists Market Summary

• The GLP-1 agonists market in the 7MM is projected to grow at a significant CAGR by 2036 in leading countries (US, EU4, UK and Japan). 

Glucagon-like Peptide-1 Agonists Market and Epidemiology Analysis

• Leading GLP-1 agonist companies such as Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Inc., Eccogene, AstraZeneca, and others are developing novel GLP-1 agonists that can be available in the GLP-1 agonists market in the coming years.
• Some of the key GLP-1 agonists include Saxenda, Enobosarm, VK2735, TERN-601, and ECC5004, among others. 
• GLP-1 agonists are a type of medication used primarily in the treatment of type 2 diabetes and sometimes for weight management. They work by imitating the action of the natural hormone glucagon-like peptide-1  (GLP-1), which helps regulate glucose levels in the blood.
• Type 2 diabetes mellitus accounts for over 85% of all diabetes cases worldwide. As of  2021, approximately 537  million adults were living with diabetes, and about 1.4  million new cases of diabetes are diagnosed in the United States every year. 
• Type  2  diabetes mellitus is more prevalent among older adults, particularly those over 65 years, where the prevalence exceeds 25%.
• Regulatory bodies approved GLP-1 receptor agonists are TRULICITY (dulaglutide), BYETTA/BYDUREON (exenatide), VICTOZA   (liraglutide),  OZEMPIC/WEGOVY/RYBELSUS, (Semaglutide), MOUNJARO/ZEPBOUND (tirzepatide) and others.
• In August 2025, Novo Nordisk announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding cirrhosis, in combination with diet and exercise. The approval was granted based on demonstrated improvements in MASH and fibrosis, and a confirmatory study is currently underway.
• In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July. A Phase I clinical trial is anticipated to start in Q3 2025.
• In April 2025, Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND meeting, supporting the advancement of its EL-22 program in combination with GLP-1 receptor agonists toward a Phase 2 clinical trial.

Request for unlocking the Sample Page of the “GLP-1 agonists Market”

DelveInsight’s “Glucagon-like Peptide-1 (GLP-1) Agonists Market Size, Target Population, Competitive Landscape and Market Forecast - 2036” report delivers an in-depth understanding of Glucagon-like Peptide-1 (GLP-1) Agonists, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The GLP-1 agonists market report provides insights around existing treatment practices in patients with Glucagon-like Peptide-1 (GLP-1) Agonists, approved (if any) and emerging Glucagon-like Peptide-1 (GLP-1) Agonists, market share of individual therapies, patient pool eligible for treatment with Glucagon-like Peptide-1 (GLP-1) Agonists, along with current and forecasted 7MM Glucagon-like Peptide-1 (GLP-1) Agonists market size from 2020-2034 by therapies and by indication. The GLP-1 agonists drugs market report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new Glucagon-like Peptide-1 (GLP-1) Agonists in different geographies, along with insights on Glucagon-like Peptide-1 (GLP-1) Agonists pricing reimbursements to curate the best opportunities and assess the market’s potential.

GLP-1 Agonists Treatment Market

This segment will provide detailed information beginning with the inhibitor journey from the discovery of the mutation or protein expression to its entry into clinical development, followed by its upcoming commercial potential. This segment will dive into the different indications for which the inhibitor is being developed, which would further provide insights into the potentially addressable patient population. Moreover, this segment will also give a brief overview of the existing treatment paradigm of the target indications.

Glucagon-like Peptide-1 (GLP-1) Agonists in Clinical Practice 

This section will give in-depth information about the existing local and systemic options in the current treatment paradigm for all the potential indications, in which most pharmaceutical companies are actively evaluating their inhibitors. The potential of the emerging Glucagon-like Peptide-1 (GLP-1) Agonists in changing the current clinical practice guidelines is crucial to analyze, especially when it comes to real-world scenarios.

It will also include the relevance and importance of incorporation of biomarker testing at varying stages of the disease. It is also important to understand that implementing such tests in routine clinical practice is not uniform in different countries due to issues such as cost, accessibility, reimbursement, and non-recommendation in guidelines.

Glucagon-like Peptide-1 (GLP-1) Agonists Recent Developments

• In June 2026, Viking Therapeutics announced on June 24 the initiation of its Phase 1 clinical trial evaluating VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA). Following FDA clearance of its IND application, the randomized, double-blind, single ascending dose study will evaluate the safety, tolerability, and body weight changes in healthy adults with a BMI of 30 or greater. VK3019 is being positioned as a potential standalone weight-loss option or a complementary agent alongside existing GLP-1/GIP therapies.
• In June 2026, Innogen announced it will present full Phase IIb results from its ENLIGHT clinical trial at the 2026 American Diabetes Association (ADA) Scientific Sessions. The study evaluates efsubaglutide alfa, the company's long-acting GLP-1 receptor agonist intended for patients managing type 2 diabetes. The presentation will detail the drug's efficacy in lowering HbA1c (average blood sugar levels over three months), weight reduction metrics, and its overall safety and tolerability profile compared to existing therapies. Securing an oral or poster presentation at the prestigious ADA sessions highlights the medical community's interest in efsubaglutide alfa as a competitive, convenient weekly or monthly treatment alternative in a highly dynamic metabolic disease market.
• In May 2026, Novo Nordisk is set to showcase its expansive cardiometabolic and diabetes pipeline at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, presenting a total of 40 abstracts. A central highlight includes the highly anticipated Phase 3 results from the REIMAGINE 1, 2, and 3 clinical trials evaluating CagriSema, a novel fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide. The data will underscore CagriSema's efficacy in achieving superior glycemic control and weight reduction compared to existing monotherapies. Additionally, Novo Nordisk will present mid-stage Phase 2 results for zenagamtide, an investigational peptide therapy targeting metabolic disorders. The presentations will also feature extensive real-world data and post hoc analyses on flagship therapies Ozempic and Wegovy, exploring their broader therapeutic benefits across co-morbidities, including significant reductions in asthma exacerbations and enhanced cardiovascular and chronic kidney disease protection.
• In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). In the multiple ascending dose study, participants receiving the highest dose level of 48 mg achieved a striking mean body-weight reduction of 9.1% by Day 54, with weight loss trends showing no signs of plateauing. Beyond weight management, DA-1726 demonstrated notable improvements in non-invasive liver biomarkers, including significant reductions in liver stiffness, Controlled Attenuation Parameter (CAP) scores, and FibroScan-AST (FAST) scores. These early indicators validate the compound’s dual mechanism, which leverages GLP-1 for appetite suppression and glucagon to accelerate energy expenditure and fat reduction in the liver, positioning DA-1726 as a potent contender in the metabolic therapeutic landscape.
• In May 2026, Eli Lilly announced it will present highly anticipated data on Foundayo, Mounjaro, and retatrutide at the American Diabetes Association’s (ADA) 86th Scientific Sessions. A core highlight includes the Phase 3 ACHIEVE trial results for Foundayo, an oral small-molecule GLP-1 receptor agonist taken without food or water restrictions. The trial demonstrated that Foundayo significantly outperformed oral semaglutide and dapagliflozin in managing type 2 diabetes, showing superior glycemic control and weight reduction. Lilly will also present updated patient-stratification analyses from the ATTAIN program alongside efficacy data for retatrutide, its investigational triple-hormone receptor agonist. Together, these readouts cement Lilly’s leadership in cardiometabolic care by expanding oral and injectable options for obesity and diabetes management.
• In May 2026, Innogen announced it will present full Phase IIb results from its ENLIGHT clinical trial at the 2026 American Diabetes Association (ADA) Scientific Sessions. The study evaluates efsubaglutide alfa, the company's long-acting GLP-1 receptor agonist intended for patients managing type 2 diabetes. The presentation will detail the drug's efficacy in lowering HbA1c (average blood sugar levels over three months), weight reduction metrics, and its overall safety and tolerability profile compared to existing therapies. Securing an oral or poster presentation at the prestigious ADA sessions highlights the medical community's interest in efsubaglutide alfa as a competitive, convenient weekly or monthly treatment alternative in a highly dynamic metabolic disease market.
• In May 2026, PureHealth Research has introduced a new natural dietary supplement featuring berberine, formulated to support the body’s native metabolic and GLP-1 (glucagon-like peptide-1) pathways amid rising global interest in weight management and metabolic health. By leveraging berberine's documented ability to influence cellular energy regulation and glucose metabolism, this botanical product is positioned as an accessible, scientifically backed holistic alternative to naturally manage blood sugar levels and support sustainable wellness without relying solely on synthetic pharmaceuticals

• In December 2025, Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of two Phase III clinical studies of Mazdutide, the world's first approved glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist, in Chinese adults with type 2 diabetes (T2D) (DREAMS-1, DREAMS-2) have been published back-to-back in Nature as Accelerated Article Previews (AAP).

• In August 2025, Novo Nordisk announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding cirrhosis, in combination with diet and exercise. The approval was granted based on demonstrated improvements in MASH and fibrosis, and a confirmatory study is currently underway.
• In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July. A Phase I clinical trial is anticipated to start in Q3 2025.
• In April 2025, Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND meeting, supporting the advancement of its EL-22 program in combination with GLP-1 receptor agonists toward a Phase 2 clinical trial.
• In July 2024, MHRA approved GLP-1 receptor agonist semaglutide to reduce the risk of serious heart problems in obese or overweight adults, and semaglutide becomes the first we• igh58 t loss drug approved in the UK as a preventative treatment for those with established cardiovascular disease.
• In July 2024, Roche announced that its oral GLP-1 receptor agonist showed promising early weight loss results in Phase I.

GLP-1 Agonists Target Patient Pool Analysis:

• In a study by Watanabe et al. (2023), between 2014 and 2018, only TRULICITY and VICTOZA had more than 5,000 annual users. OZEMPIC users grew from 569 in 2019 to 7,667 in 2020, then surged to over 13,310 in 2021, surpassing TRULICITY. By 2022, OZEMPIC reached 22,891 users. WEGOVY increased from 989 users in 2021 to 2,992 in 2022, while MOUNJARO reached 1,508 users in 2022. Similar trends were noted across T2D, CVD, and overweight/obese subgroups, with OZEMPIC’s prominence most evident in the overweight/obese group. Monthly growth rates were 83.9% for OZEMPIC, 119.2% for WEGOVY, 84.8% for RYBELSUS, 12.9% for ADLYXIN, 78.8% for TRULICITY, and 254.3% for MOUNJARO.
• Type 2 diabetes mellitus represents more than 85% of all diabetes cases globally. In 2021, roughly 537 million adults were living with diabetes, and approximately 1.4 million new cases are diagnosed annually in the United States.
• According to a 2024 study by Duo Do et al., the overall 12-month discontinuation rate for GLP-1 agonists is estimated at 36.5%, with higher rates observed in patients with obesity alone compared to those with type 2 diabetes. Increased discontinuation was associated with younger age, female gender, and higher out-of-pocket expenses.
• Sen et al. (2024) reported that the use of a once-weekly GLP-1 receptor agonist was independently linked to a 30.5% higher prevalence of elevated residual gastric content on preprocedural gastric ultrasonography, which is a significant risk factor for aspiration during anesthesia.

Glucagon-like Peptide-1 (GLP-1) Agonists Drug Chapters

The drug chapter segment of the GLP-1 agonists drug market report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the Glucagon-like Peptide-1 (GLP-1) Agonists clinical trial details, pharmacological action, agreements and collaborations related to Glucagon-like Peptide-1 (GLP-1) Agonists, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

GLP-1 Agonists Marketed Drugs

The Glucagon-like Peptide-1 (GLP-1) Agonists marketed drug section will provide detailed drug profiles of already approved therapies.  Information around clinical development activities, launch timing, regulatory milestones along with safety and efficacy data of the therapy will be included. Glucagon-like peptide-1 agonists (GLP-1RA, GLP-1DAs, incretin mimetics, or GLP-1 analogs) represent a category of therapeutics used in the treatment of type 2 diabetes mellitus (T2DM) and obesity. These medications, through their mechanism of action, contribute to the reduction of serum glucose levels and thus play a role in regulating metabolic processes in patients with these endocrine conditions.

Other functions of GLP-1 include increased glucose uptake in the muscles, decreased glucose production in the liver, neuroprotection, and increased satiety due to direct actions on the hypothalamus.

In Type 2 diabetes, GLP-1 agonists help manage blood sugar by triggering the pancreas to release more insulin. The slowed digestion also helps decrease blood sugar spikes, and the satiety effect of GLP1- agonists reduces food intake, appetite, and hunger. These combined effects often result in weight loss.

Regulatory bodies approved GLP-1 receptor agonists for glycemic control include:

Dulaglutide (subcutaneous-SC), exenatide injectable solution subcutaneous, exenatide injectable suspension SC, liraglutide SC, liraglutide/insulin degludec , lixisenatide/insulin glargine, semaglutide (oral, SC), tirzepatide (dual GIP/GLP-1 receptor agonist) and others.

Regulatory bodies approved GLP-1 agonists for weight loss include: Semaglutide SC, liraglutide SC

GLP-1 Agonists Emerging Drugs

Apart from a comprehensive Glucagon-like Peptide-1 (GLP-1) Agonists competitive landscape in tabular form, the emerging drug chapters provide the product details and other development activities of the emerging Glucagon-like Peptide-1 (GLP-1) Agonists under the late and mid-stage of clinical development for various indications. Some of the GLP-1 agonists drugs in the pipeline include orforglipron by Eli Lilly and company, survodutide by Boehringer Ingelheim, danuglipron by Pfizer, and retatrutide by Eli Lilly and company, among others.

Orforglipron (LY3502970): Eli Lilly

Orforglipron (LY3502970) is a chemical entity that acts as an agonist for the GLP-1 receptor. It is being studied for the treatment of type 2 diabetes and obesity. The drug is currently being evaluated in Phase III clinical development.

• In June 2025, Eli Lilly reported Phase III ACHIEVE-1 results showing that oral GLP-1 agonist orforglipron significantly reduced A1C at all doses and induced weight loss at 12 mg and 36 mg versus placebo, with a safety profile consistent with the GLP-1 class. The results were presented at the American Diabetes Association (ADA) 85th Scientific Sessions 2025 and simultaneously published in The New England Journal of Medicine.

Survodutide (BI 456906): Boehringer Ingelhium

Survodutide (BI 456906) is a GCGR/GLP1 dual agonist being developed by Boehringer Ingelhium. Both receptors are critical to controlling metabolic functions. The compound leverages the known effects of the natural gut hormone oxyntomodulin, which has been shown to decrease food intake and increase energy expenditure in humans as well as the established effects of GLP1 agonism on both glucose control and body weight. The drug is currently in Phase III.

• In October 2024, The US FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide’s groundbreaking results from Phase II study.

Retatrutide (LY-3437943): Eli Lilly

Retatrutide is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the GLP-1 receptor and the glucagon receptor. It is being studied for the treatment of T2DM, Obesity, Osteoarthritis, and Obstructive Sleep Apnea with a planned simultaneous submission strategy. The drug is currently being evaluated in Phase III clinical development. 

• In June 2023, Lilly announced that Retatrutide achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight and a mean weight reduction up to 24.2% at 48 weeks during phase II studies.

Note: Detailed list will be provided in the final report....

GLP-1 agonists Drug Class Insights

The Drug Class Insights section will provide comprehensive information on Glucagon-like Peptide-1 (GLP-1) Agonists as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of Glucagon-like Peptide-1 (GLP-1) Agonists, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

Glucagon-like Peptide-1 (GLP-1) Agonists Market Outlook

This section will include details on changing Glucagon-like Peptide-1 (GLP-1) Agonists market dynamics post initiation of clinical development activities of the inhibitor.  It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial’s inclusion criteria.  There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

Glucagon-like Peptide-1 (GLP-1) Agonists Drugs Uptake

This section focuses on the uptake rate of potential Glucagon-like Peptide-1 (GLP-1) Agonists already launched and expected to be launched in the GLP-1 agonists therapy market during 2020–2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Glucagon-like Peptide-1 (GLP-1) Agonists Pipeline Development Activities

The GLP-1 agonists market report provides insights into different GLP-1 agonists clinical trials within Phase III and Phase II stages. It also analyzes key GLP-1 agonists companies involved in developing targeted therapeutics. 

GLP-1 Agonists Pipeline Development Activities

The GLP-1 agonists therapeutics market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Glucagon-like Peptide-1 (GLP-1) Agonists.

Latest KOL Views on GLP-1 agonists

To keep up with current and future GLP-1 agonists market trends, we incorporate Key physicians, Therapy Area Researcher’s, and other Industry Experts’ opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on Glucagon-like Peptide-1 (GLP-1) Agonists’ incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst’s discretion and assessment of the cost analysis and existing and evolving treatment landscape.

GLP-1 agonists Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the GLP-1 agonists Market Report

• The GLP-1 agonists drug market report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on Glucagon-like Peptide-1 (GLP-1) Agonists addressable patient pool 
• A detailed review of the Glucagon-like Peptide-1 (GLP-1) Agonists market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The GLP-1 agonists market report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM Glucagon-like Peptide-1 (GLP-1) Agonists market.
• GLP-1 agonists Market Size of Inhibitors by therapies and indication will be provided 

Glucagon-like Peptide-1 (GLP-1) Agonists Market Report Key Strengths

• 10 Years Glucagon-like Peptide-1 (GLP-1) Agonists Market Forecast
• The 7MM Coverage
• Glucagon-like Peptide-1 (GLP-1) Agonists Competitive Landscape of current and emerging therapies
• Glucagon-like Peptide-1 (GLP-1) Agonists Total Addressable patient population 
• GLP-1 agonists Drugs Uptake and Key GLP-1 agonists Market Forecast Assumptions
• Approved and Emerging GLP-1 agonists therapy Profiles
• Physician’s perspectives/KOL opinions
• Biomarker testing and GLP-1 agonists Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• GLP-1 agonists Market Size by therapy and indication
• Existing and Future GLP-1 agonists Market Opportunity
• GLP-1 agonists Unmet Needs

Key Questions Answered in the GLP-1 agonists Market Report

• What was the GLP-1 agonists market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for Glucagon-like Peptide-1 (GLP-1) Agonists market growth?
• Which GLP-1 agonists drug is going to be the largest contributor by 2034?
• What is the GLP-1 agonists market access and reimbursement scenario of Glucagon-like Peptide-1 (GLP-1) Agonists?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the GLP-1 agonists market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy GLP-1 agonists Market Forecast Report:

• The GLP-1 agonists market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Glucagon-like Peptide-1 (GLP-1) Agonists Market.
• Understand the existing Glucagon-like Peptide-1 (GLP-1) Agonists market opportunities  and future trends in varying geographies 
• Identifying strong upcoming GLP-1 agonists companies in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility and acceptability of emerging treatment options along with GLP-1 agonists unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies’ development and launch strategy.